Plasma renin activity, response to aliskiren, and clinical outcomes in patients hospitalized for heart failure: the ASTRONAUT trial

AIMS: The direct renin inhibitor, aliskiren, is known to reduce plasma renin activity (PRA), but whether the efficacy of aliskiren varies based on an individual’s baseline PRA in patients hospitalized for heart failure (HF) is presently unknown. We characterized the prognostic value of PRA and deter...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Eur J Heart Fail
Auteurs principaux: Vaduganathan, Muthiah, Cheema, Baljash, Cleveland, Erin, Sankar, Kamya, Subacius, Haris, Fonarow, Gregg C., Solomon, Scott D., Lewis, Eldrin F., Greene, Stephen J., Maggioni, Aldo P., Böhm, Michael, Zannad, Faiez, Butler, Javed, Gheorghiade, Mihai
Format: Artigo
Langue:Inglês
Publié: 2017
Sujets:
Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC6676477/
https://ncbi.nlm.nih.gov/pubmed/29143416
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/ejhf.973
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires